Arcutis Biotherapeutics, Inc.
ARQT
Rankning i aktier
#3988
Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to... Arcutis Biotherapeutics, Inc. is a biopharmaceutical firm dedicated to developing and marketing therapies for a range of skin-related diseases. The company's flagship investigational compound, ARQ-151, a roflumilast cream administered topically, has successfully concluded late-stage clinical development for treating both plaque psoriasis and atopic dermatitis. Beyond its lead asset, Arcutis's pipeline includes several other promising compounds. Among these is ARQ-154, a roflumilast foam applied topically, aimed at seborrheic dermatitis and scalp psoriasis. Furthermore, ARQ-252, a topical selective Janus kinase type 1 (JAK1) inhibitor, is under investigation for hand eczema and vitiligo. ARQ-255, a variation of ARQ-252 designed for deeper dermal absorption, is being explored for alopecia areata. Established in 2016, the company was initially named Arcutis, Inc. before changing to Arcutis Biotherapeutics, Inc. in October 2019. Its corporate headquarters are situated in Westlake Village, California.
Aktiekurs
$32.88
Marknadsvärde
$4.13B
Förändring (1 dag)
3.11%
Förändring (1 år)
57.49%
Land
US
Handel Arcutis Biotherapeutics, Inc. (ARQT)
Kategori
Healthcare
Vinst för Arcutis Biotherapeutics, Inc. (ARQT)
Vinst i Jun 2026 TTM: $29.30M
Enligt de senaste finansiella rapporterna från Arcutis Biotherapeutics, Inc. är företagets nuvarande vinst $29.30M. År 2023 hade företaget en vinst på $-259.03M, en ökning jämfört med vinsten år 2022 som var $-311.46M. Vinsten som visas på denna sida är vinsten före räntor och skatt, även kallad EBIT.
Vinshistorik för Arcutis Biotherapeutics, Inc. från 2017 till 2026
Vinst vid slutet av varje år
| År | Vinst | Ändra |
|---|---|---|
| 2026 (TTM) | $29.30M | -121.02% |
| 2024 | $-139.39M | -46.19% |
| 2023 | $-259.03M | -16.83% |
| 2022 | $-311.46M | 50.93% |
| 2021 | $-206.36M | 52.09% |
| 2020 | $-135.68M | 223.07% |
| 2019 | $-42.00M | 118.10% |
| 2018 | $-19.26M | 286.80% |
| 2017 | $-4.98M | 0.00% |
Vinst för liknande företag eller konkurrenter
| Företag | Vinst | Skillnad i vinst | Land |
|---|---|---|---|
| $5.27B | 17,904.30% |
US
|
|
| $-3.09B | -10,636.56% |
US
|
|
| $-4.02B | -13,808.09% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | 6,557.96% |
NL
|
